Table 1 Patient demographics and baseline characteristics.

From: Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol

Characteristics

Corifollitropin alfa/PPOS protocol (n = 173)

Corifollitropin alfa/GnRHant protocol (n = 160)

P value

Total no. of cycles

173

160

 

Age (y)

34.2 ± 2.8

34.4 ± 2.6

0.549

Body weight (kg)

55.8 ± 3.8

55.7 ± 3.7

0.795

Body mass index (kg/m2)

22.4 ± 1.8

22.4 ± 1.7

0.950

Duration of infertility (y)

3.4 ± 1.5

3.5 ± 1.6

0.844

Proportion of primary infertility (%)

80.1 (140/173)

85.0 (136/160)

0.382

AMH (ng/mL)

9.7 ± 4.2

10.1 ± 5.3

0.401

Baseline hormonal profiles

FSH (IU/L)

5.7 ± 1.4

5.8 ± 1.5

0.286

LH (IU/L)

6.5 ± 2.3

6.1 ± 2.5

0.166

E2 (pg/mL)

40.2 ± 17.6

41.8 ± 16.8

0.392

Progesterone (ng/mL)

0.65 ± 0.25

0.69 ± 0.22

0.149

Testosterone (ng/dL)

34.5 ± 18.0

35.6 ± 17.4

0.553

  1. Values are expressed as number, mean ± standard deviation or percentage.
  2. PPOS progestin primed ovarian stimulation, GnRHant GnRH antagonist, AMH anti-Mullerian hormone, FSH follicle-stimulating hormone, LH luteinizing hormone, E2 Estradiol.
Back to article page